Neurogene Inc. NGNE
Neurogene Inc. (Nasdaq: NGNE) is a CNS/neurology/psychiatry drug developer. Its lead program, NGN-401, is in Phase 2 for Rett syndrome. Its next catalyst on record is NGN-401: Complete process performance qualification (PPQ) runs (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NGN-401 — Complete process performance qualification (PPQ) runs (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NGN-401 (Embolden registrational trial; Phase 1/2 completed dosing) | Rett syndrome | gene therapy | Phase 2 |
| NGN-101 (de-prioritized Nov 2024; options being evaluated) | CLN5 Batten disease | gene therapy | Phase 1 |
| EXACT platform discovery programs | other neurological diseases | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.